Value of serum free prostate specific antigen in predicting prognosis in patients with benign prostatic hyperplasia

ZENG Ke; XIE Wenxian; YANG Jian; LI Xiaobin; LIU Yuejiang; CHEN Rong; DENG Kefei; WANG Tifen

doi:10.7619/jcmp.20212093

Journal of Clinical Medicine in Practice > 2022 > 26(5): 39-43. > DOI: 10.7619/jcmp.20212093

ZENG Ke, XIE Wenxian, YANG Jian, LI Xiaobin, LIU Yuejiang, CHEN Rong, DENG Kefei, WANG Tifen. Value of serum free prostate specific antigen in predicting prognosis in patients with benign prostatic hyperplasia[J]. Journal of Clinical Medicine in Practice, 2022, 26(5): 39-43. DOI: 10.7619/jcmp.20212093

Citation:

PDF (828 KB)

Value of serum free prostate specific antigen in predicting prognosis in patients with benign prostatic hyperplasia

1.
Department of Urinary Surgery, Zigong City First People's Hospital of Sichuan Province, Zigong, Sichuan, 643000
2.
Department of Basic Medicine, Sichuan Vocational College of Health and Rehabilitation, Zigong, Sichuan, 643000
3.
Department of Anesthesiology, Neijiang City Second People's Hospital of Sichuan Province, Neijiang, Sichuan, 641000

More Information

Received Date: May 18, 2021
Available Online: March 28, 2022
Published Date: March 14, 2022

Graphical Abstract

Abstract

Abstract

Objective To investigate the change of serum free prostate specific antigen (fPSA) in patients with benign prostatic hyperplasia (BPH) after transurethral enucleative resection of prostate (TUERP) and its relationships with prostate volume and prognosis.
Methods A total of 105 BPH patients with TUERP were divided into small volume group (n=49), medium volume group (n=36) and large volume group (n=20) according to preoperative prostate volume. The levels of serum fPSA were compared among three groups before operation and 1 day, 3 and 7 days after operation. The relationship between preoperative serum fPSA level and prostate volume was analyzed by Pearson method. The clinical materials and the level of serum fPSA at 7 days after operation were compared among BPH patients with different prognosis. Logistic regression analysis was used to explore the influencing factors of poor prognosis in BPH patients.
Results Before operation and 1 day after operation, the levels of serum fPSA in the small volume group, the medium volume group and the large volume group increased significantly (P < 0.05). Pearson analysis showed that there was a positive correlation between preoperative serum fPSA level and prostate volume in patients with BPH (r=0.598, P < 0.05). Compared with the good prognosis group (n=79), the high density lipoprotein cholesterol (HDL-C), blood glucose, serum fPSA level at 7 days after operation and the ratio of cases with hypertension in the poor prognosis group (n=26) were significantly higher (P < 0.05). Logistic regression analysis showed that HDL-C, blood glucose, hypertension and serum fPSA at 7 days after operation were the risk factors for the prognosis of BPH patients (P < 0.05).
Conclusion The serum fPSA level is highly expressed in BPH patients, which may be involved in the pathogenesis of BPH. The serum fPSA level at 7 days after operation can be used to evaluate the prognosis of BPH patients after TUERP.

FullText(HTML)

References (27)

References

[1]	XUAN H N, HUY H D, BICH N N T, et al. Anatomical characteristics and variants of prostatic artery in patients of benign hyperplasia prostate by digital subtraction angiography[J]. Open Access Maced J Med Sci, 2019, 7(24): 4204-4208. doi: 10.3889/oamjms.2019.361
[2]	SPIRINA L V, KOVALEVA I V, USYNIN E A, et al. Progesterone receptor expression in the benign prostatic hyperplasia and prostate cancer tissues, relation with transcription, growth factors, hormone reception and components of the AKT/mTOR signaling pathway[J]. Asian Pac J Cancer Prev, 2020, 21(2): 423-429. doi: 10.31557/APJCP.2020.21.2.423
[3]	SCHÖB D S, REICHELT A C, GROSS A J, et al. Novel surgical techniques for treatment of benign prostatic hyperplasia[J]. Urologe A, 2020, 59(3): 347-358. doi: 10.1007/s00120-020-01149-1
[4]	石爱军, 江开航, 陈金叶, 等. 前列腺癌与前列腺增生的影像学诊断研究[J]. 局解手术学杂志, 2017, 26(9): 682-686. https://www.cnki.com.cn/Article/CJFDTOTAL-JJXZ201709015.htm
[5]	FU S, ZHANG X, NIU Y, et al. Prostate specific antigen, mean platelet volume, and platelet distribution width in combination to discriminate ProstateCancer from benign prostate hyperplasia[J]. Asian Pac J Cancer Prev, 2018, 19(3): 699-702.
[6]	张树江, 孙祖越. PSA与前列腺癌发展和转移相关性的研究进展[J]. 中华男科学杂志, 2018, 24(5): 457-461. https://www.cnki.com.cn/Article/CJFDTOTAL-NKXB201805018.htm
[7]	琚建军, 李云, 郑军荣, 等. 急性前列腺炎前列腺特异抗原和炎症指标的动态变化规律及意义[J]. 山西医药杂志, 2018, 47(23): 2789-2792. doi: 10.3969/j.issn.0253-9926.2018.23.005
[8]	李倩. 前列腺疾病患者游离前列腺特异性抗原比率检测结果分析[J]. 检验医学与临床, 2013, 10(24): 3341-3342. doi: 10.3969/j.issn.1672-9455.2013.24.047
[9]	何斌, 倪浩东, 唐庆生, 等. 经尿道前列腺等离子剜除术与经尿道前列腺电切术治疗前列腺增生临床疗效分析[J]. 中国现代手术学杂志, 2018, 22(1): 52-55. https://www.cnki.com.cn/Article/CJFDTOTAL-XDSS201801015.htm
[10]	高卫军, 成慧霞, 贺艳锋. 经尿道前列腺电切术与经尿道双极等离子电切术治疗良性前列腺增生的临床效果比较[J]. 西北国防医学杂志, 2018, 39(5): 332-334. https://www.cnki.com.cn/Article/CJFDTOTAL-XBGY201805018.htm
[11]	斯钦布和, 易发现, 王国强, 等. 经尿道前列腺剜除术治疗良性前列腺增生疗效观察[J]. 局解手术学杂志, 2019, 28(11): 891-895. https://www.cnki.com.cn/Article/CJFDTOTAL-JJXZ201911010.htm
[12]	YU Y, LOU G T, SHEN C, et al. Technical aspects of transurethral plasmakinetic enucleation and resection of the prostate for benign prostatic hyperplasia[J]. Minim Invasive Ther Allied Technol, 2017, 26(1): 44-50. doi: 10.1080/13645706.2016.1227851
[13]	《泌尿外科杂志(电子版)》编辑部. 《良性前列腺增生诊断治疗指南》解读: 治疗篇[J]. 泌尿外科杂志: 电子版, 2011, 3(4): 47-50. doi: 10.3969/j.issn.1674-7410.2011.04.017
[14]	范本, 齐范, 李文泽, 等. 湖南地区不同年龄、不同前列腺体积与血清中PSA及fPSA水平的相关性研究[J]. 实用预防医学, 2011, 18(11): 2034-2035. doi: 10.3969/j.issn.1006-3110.2011.11.002
[15]	HU J M, ZHANG L M, ZOU L J, et al. Role of inflammation in benign prostatic hyperplasia development among Han Chinese: a population-based and single-institutional analysis[J]. Int J Urol, 2015, 22(12): 1138-1142. doi: 10.1111/iju.12914
[16]	GE Y Q, WANG Q D, SHAO W, et al. Circulating let-7f-5p improve risk prediction of prostate cancer in patients with benign prostatic hyperplasia[J]. J Cancer, 2020, 11(15): 4542-4549. doi: 10.7150/jca.45077
[17]	CHEN B, CAO D H, CHEN Z Y, et al. Estrogen regulates the proliferation and inflammatory expression of primary stromal cell in benign prostatic hyperplasia[J]. Transl Androl Urol, 2020, 9(2): 322-331. doi: 10.21037/tau.2020.02.08
[18]	魏希锋. 经尿道等离子前列腺剜除术的研究进展[J]. 国际泌尿系统杂志, 2016(2): 248-250. doi: 10.3760/cma.j.issn.1673-4416.2016.02.027
[19]	王锋. 经尿道前列腺电切术与经尿道前列腺剜除术治疗大体积前列腺增生的安全性及有效性分析[J]. 实用医院临床杂志, 2018, 15(4): 199-201. doi: 10.3969/j.issn.1672-6170.2018.04.065
[20]	YVCEL C, BUDAK S, KISA E, et al. The sufficiency of 6 core sextant prostate biopsy in patients with prostate specific antigen (PSA) values over 20 ng/mL[J]. Arch Ital UrolAndrol, 2018, 90(2): 104-106. doi: 10.4081/aiua.2018.2.104
[21]	SJOBERG D D, VICKERS A J, ASSEL M, et al. Twenty-year risk of prostate cancer death by midlife prostate-specific antigen and a panel of four kallikrein markers in a large population-based cohort of healthy men[J]. Eur Urol, 2018, 73(6): 941-948. doi: 10.1016/j.eururo.2018.02.016
[22]	李林, 阎成全, 翟玉普, 等. 血清总前列腺特异性抗原、血清游离前列腺特异性抗原与总特异性抗原的比值在前列腺癌中的诊断价值[J]. 中国煤炭工业医学杂志, 2017, 20(9): 1035-1038. https://www.cnki.com.cn/Article/CJFDTOTAL-ZMGY201709011.htm
[23]	WANG X J, AN P, ZENG J L, et al. Serum ferritin in combination with prostate-specific antigen improves predictive accuracy for prostate cancer[J]. Oncotarget, 2017, 8(11): 17862-17872. doi: 10.18632/oncotarget.14977
[24]	孟元, 卫中庆, 熊红兵, 等. 良性前列腺增生伴组织学炎症与PSA异常升高的相关性[J]. 江苏医药, 2013, 39(17): 2016-2018. https://www.cnki.com.cn/Article/CJFDTOTAL-YIYA201317012.htm
[25]	PEJCIC T P, TULIC C D Z, LALIC N V, et al. Urinary prostate-specific antigen: predictor of benign prostatic hyperplasia progression[J]. Can J Urol, 2013, 20(2): 6707-6713.
[26]	蒋团建, 黄仁胜. 血清PSA水平在良性前列腺增生患者术后预后判断中的价值[J]. 中国民康医学, 2019, 31(10): 124-126. doi: 10.3969/j.issn.1672-0369.2019.10.055
[27]	COBAN S, DOLUOGLU O G, KELES I, et al. Age and total and free prostate-specific antigen levels for predicting prostate volume in patients with benign prostatic hyperplasia[J]. Aging Male, 2016, 19(2): 124-127. doi: 10.3109/13685538.2015.1131260

[1]	WANG Mingbang, CHEN Changsha, LIU Rongzhen, XU Jianfeng. Effect of transurethral plasmakinetic resection of prostate in treating benign prostatic hyperplasia complicated with hypertension[J]. Journal of Clinical Medicine in Practice, 2024, 28(15): 90-94. DOI: 10.7619/jcmp.20241211
[2]	LI Meng, ZHANG Wenfeng, WU Wenfeng, JIANG Tao, WEN Lili. Transurethral green laser enucleation of prostate versus transurethral vaporization of prostate in treatment of severe benign prostatic hyperplasia[J]. Journal of Clinical Medicine in Practice, 2023, 27(2): 113-116, 121. DOI: 10.7619/jcmp.20214804
[3]	WU Haoming, FU Guangbo. Clinical significance of long non-coding RNA SChLAP1 expression in prostate cancer tissue and its relationship with prognosis[J]. Journal of Clinical Medicine in Practice, 2022, 26(5): 30-33. DOI: 10.7619/jcmp.20214427
[4]	PAN Kai, SHEN Yuyong, ZHOU Hai, CHEN Yuming, QI Lezhong, FAN Qibing, QI Tingyue, WANG Xiaoxiang. Modified holmium laser enucleation of the prostate versus transurethral resection of prostate in treatment patients with large volume prostatic hyperplasia[J]. Journal of Clinical Medicine in Practice, 2020, 24(11): 21-24. DOI: 10.7619/jcmp.202011006
[5]	DONG Xinqiang, SUN Wengong, CUI Hongquan, PENG Yingke. Effect of dilatation surgery of prostate on sexual function in benign prostatic hyperplasia patients[J]. Journal of Clinical Medicine in Practice, 2020, 24(2): 65-67. DOI: 10.7619/jcmp.202002019
[6]	ZHANG Shaojie, XU Xiaofeng, DU Quan, LI Nan, XIAO Xiang. Effect of transurethral plasma bipolar resection of prostate on urodynamics and serum levels of prostate specific antigen, epidermal growth factor and prostaglandin E₂ in patients with benign prostatic hyperplasia[J]. Journal of Clinical Medicine in Practice, 2019, 23(18): 79-83. DOI: 10.7619/jcmp.201918023
[7]	ZENG Hanyun. Clinical nursing pathway in treating benign prostatic hyperplasia patients with transurethral resection[J]. Journal of Clinical Medicine in Practice, 2019, 23(13): 123-125, 128. DOI: 10.7619/jcmp.201913035
[8]	ZHOU Cuiyu, LIU Weihua. Evidence-based nursing for transurethral resection of prostate in elderly patients underwent benign prostatic hyperplasia[J]. Journal of Clinical Medicine in Practice, 2019, 23(7): 116-120. DOI: 10.7619/jcmp.201907031
[9]	WANG Yongheng, ZHANG Xueguang. Effect of transurethral plasma prostate gland resection on the treatment of benign prostatic hyperplasia[J]. Journal of Clinical Medicine in Practice, 2018, (7): 99-101. DOI: 10.7619/jcmp.201807027
[10]	LUO Qing, JIANG Jinxiong, CAO Xiaozhen, XIAO Qinghua. Differential diagnostic value of transrectal ultrasound combined with PSAD on prostate cancer and benign prostate hyperplsia[J]. Journal of Clinical Medicine in Practice, 2013, (13): 156-158. DOI: 10.7619/jcmp.201313057

Cited By

Cited by

Periodical cited type(2)

1.	喻洁明，任荣飞，陈晓亮. 耳内镜下应用耳屏软骨-软骨膜复合体行Ⅰ型鼓室成形术的临床疗效研究. 中国医学文摘(耳鼻咽喉科学). 2024(01): 130-132+108 .
2.	包勇正，邹文兰，胡志邦，马敬. 29例鼓膜大穿孔患者耳内镜下鼓膜成形术疗效观察. 实用临床医药杂志. 2020(23): 42-44 . 本站查看

Other cited types(0)

Get Citation

PDF

XML

Article views (219) PDF downloads (17) Cited by(2)

Turn off MathJax

Article Contents

Abstract

References

Value of serum free prostate specific antigen in predicting prognosis in patients with benign prostatic hyperplasia